PROCEPT BioRobotics Corporation (PRCT) reported first-quarter 2026 results with total revenue of $83.1 million, up 20.2% year-over-year.
Diluted loss per share was -$0.56, an improvement of 24.4% from a year earlier and slightly better than the consensus estimate of -$0.57.
The company topped the revenue estimate of $82.1 million, beating consensus by about $1.0 million. Shares reacted strongly, rising 19.3% since market close.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
PROCEPT BioRobotics Corporation Insider Trading Activity
PROCEPT BioRobotics Corporation insiders have traded $PRCT stock on the open market 13 times in the past 6 months. Of those trades, 7 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $PRCT stock by insiders over the last 6 months:
- ANTAL ROHIT DESAI has made 7 purchases buying 426,262 shares for an estimated $10,482,942 and 0 sales.
- ALALEH NOURI (EVP, CLO, CORP. SEC.) has made 0 purchases and 4 sales selling 12,559 shares for an estimated $311,142.
- KEVIN WATERS (EVP, CFO) has made 0 purchases and 2 sales selling 7,427 shares for an estimated $179,176.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
PROCEPT BioRobotics Corporation Hedge Fund Activity
We have seen 159 institutional investors add shares of PROCEPT BioRobotics Corporation stock to their portfolio, and 106 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 3,382,944 shares (-42.1%) from their portfolio in Q4 2025, for an estimated $106,427,418
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. added 2,002,389 shares (+183.3%) to their portfolio in Q4 2025, for an estimated $62,995,157
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 1,970,147 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $61,980,824
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,667,045 shares (-81.2%) from their portfolio in Q4 2025, for an estimated $52,445,235
- PROSIGHT MANAGEMENT, LP added 1,303,009 shares (+1692.4%) to their portfolio in Q4 2025, for an estimated $40,992,663
- LOOMIS SAYLES & CO L P removed 983,903 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $30,953,588
- CHICAGO CAPITAL, LLC added 969,592 shares (+81.4%) to their portfolio in Q1 2026, for an estimated $24,249,495
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
PROCEPT BioRobotics Corporation Analyst Ratings
Wall Street analysts have issued reports on $PRCT in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 12/18/2025
- UBS issued a "Buy" rating on 12/12/2025
- TD Cowen issued a "Buy" rating on 11/05/2025
To track analyst ratings and price targets for PROCEPT BioRobotics Corporation, check out Quiver Quantitative's $PRCT forecast page.
PROCEPT BioRobotics Corporation Price Targets
Multiple analysts have issued price targets for $PRCT recently. We have seen 9 analysts offer price targets for $PRCT in the last 6 months, with a median target of $30.0.
Here are some recent targets:
- David Rescott from Baird set a target price of $30.0 on 03/06/2026
- Richard Newitter from Truist Securities set a target price of $30.0 on 03/02/2026
- Craig Bijou from B of A Securities set a target price of $20.0 on 02/26/2026
- Nathan Treybeck from Wells Fargo set a target price of $34.0 on 02/26/2026
- Joshua Jennings from TD Cowen set a target price of $34.0 on 02/26/2026
- Matt O'Brien from Piper Sandler set a target price of $28.0 on 02/26/2026
- Mike Kratky from Leerink Partners set a target price of $30.0 on 02/26/2026
